A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in an Autism Spectrum Disorder Population
Latest Information Update: 03 Oct 2023
At a glance
- Drugs AB 2004 (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Acronyms TAPESTRY
- Sponsors Axial Therapeutics
- 27 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2023.
- 26 Sep 2023 According to an Axial Therapeutics media release, Roger J. Jou is the Principal Investigator of the study.
- 26 Sep 2023 According to an Axial Therapeutics media release, data from this trial is anticipated in the first quarter of 2024.